Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12342530 | 0.75 | FABP3 (0.31) | FABP3FABP4 | |
| SCHEMBL18950280 | 0.73 | TP53 (0.31) | — | |
| SCHEMBL21565625 | 0.70 | — | — | |
| SCHEMBL25129108 | 0.69 | TYR (0.39) | — | |
| SCHEMBL22252035 | 0.69 | BMPR1B (0.36) | — | |
| SCHEMBL20674834 | 0.67 | KDM4E (0.40) | — | |
| SCHEMBL10119732 | 0.65 | PTGS2 (0.47) | — | |
| SCHEMBL22252037 | 0.65 | HDAC4 (0.43) | — | |
| SCHEMBL18198118 | 0.64 | PTGS2 (0.34) | — | |
| SCHEMBL25128568 | 0.63 | MAPK1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3568133-B1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH ZUERICH (CH) | 2023-12-13 | — | — | EP | disclosed |
| WO-2019179890-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2019-09-26 | — | — | WO | disclosed |
| EP-3543231-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018130537-A1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH Zürich (CH) | 2018-07-19 | — | — | WO | disclosed |
| US-9676763-B2 | Method of treating Ebola | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676763-B2 | Method of treating Ebola | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160024066-A1 | Small Molecule Inhibitors of Ebola and Lassa Fever Viruses and Methods of Use | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2016-01-28 | — | — | US | disclosed |
| US-9193705-B2 | Small molecule inhibitors of ebola and lassa fever viruses and methods of use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-11-24 | — | — | US | disclosed |
| US-20130231332-A1 | SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-05 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024066-A1 | Small Molecule Inhibitors of Ebola and Lassa Fever Viruses and Methods of Use | LASP1, LAS1L, HSP90B1 | FABP3 1763/4885FABP4 1842/4885 |
| US-20130231332-A1 | SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE | LASP1, LAS1L, HSP90B1 | FABP3 1763/4885FABP4 1842/4885 |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | FABP3 1359/4885FABP4 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.